HeartFlow (HTFL) Revenue Growth Story Confronts Ongoing EPS Losses In Q4 2025

Simply Wall St.

Mar 20

HeartFlow (HTFL) has wrapped up FY 2025 with fourth quarter revenue of US$49.1 million and a basic EPS loss of US$0.29, while over the trailing twelve months revenue reached US$176.0 million alongside...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2620827786"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620827786\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620827786?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","is_english":true,"pubTime":"2026-03-20 06:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620827786","market":"us","top_or_hot":-1,"title":"HeartFlow (HTFL) Revenue Growth Story Confronts Ongoing EPS Losses In Q4 2025","media":"Simply Wall St.","content":"<div>\n<p>HeartFlow (HTFL) has wrapped up FY 2025 with fourth quarter revenue of US$49.1 million and a basic EPS loss of US$0.29, while over the trailing twelve months revenue reached US$176.0 million alongside...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-htfl/heartflow/news/heartflow-htfl-revenue-growth-story-confronts-ongoing-eps-lo\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HeartFlow (HTFL) Revenue Growth Story Confronts Ongoing EPS Losses In Q4 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeartFlow (HTFL) Revenue Growth Story Confronts Ongoing EPS Losses In Q4 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-20 06:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-htfl/heartflow/news/heartflow-htfl-revenue-growth-story-confronts-ongoing-eps-lo><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HeartFlow (HTFL) has wrapped up FY 2025 with fourth quarter revenue of US$49.1 million and a basic EPS loss of US$0.29, while over the trailing twelve months revenue reached US$176.0 million alongside...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-htfl/heartflow/news/heartflow-htfl-revenue-growth-story-confronts-ongoing-eps-lo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HTFL","symbol_name":"HeartFlow Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-htfl/heartflow/news/heartflow-htfl-revenue-growth-story-confronts-ongoing-eps-lo","article_id":"2620827786","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-htfl/heartflow/news/heartflow-htfl-revenue-growth-story-confronts-ongoing-eps-lo","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620827786","pubTimestamp":1773958631,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"HeartFlow (HTFL) has wrapped up FY 2025 with fourth quarter revenue of US$49.1 million and a basic EPS loss of US$0.29, while over the trailing twelve months revenue reached US$176.0 million alongside a basic EPS loss of US$3.17. The company has seen revenue move from US$125.8 million on a trailing basis in Q4 2024 to US$176.0 million in Q4 2025, with EPS remaining in loss-making territory over that period, which keeps the focus squarely on how fast the top line can scale against ongoing net...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"HTFL":"HeartFlow Inc"},"translate_title":"HeartFlow(HTFL)收入增长故事面临2025年第四季度每股收益持续亏损","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HTFL":1.5},"content_text":"HeartFlow (HTFL) has wrapped up FY 2025 with fourth quarter revenue of US$49.1 million and a basic EPS loss of US$0.29, while over the trailing twelve months revenue reached US$176.0 million alongside a basic EPS loss of US$3.17. The company has seen revenue move from US$125.8 million on a trailing basis in Q4 2024 to US$176.0 million in Q4 2025, with EPS remaining in loss-making territory over that period, which keeps the focus squarely on how fast the top line can scale against ongoing net losses. For investors, the story here is about whether revenue momentum can eventually compress those losses and pull margins in a more sustainable direction. See our full analysis for HeartFlow. With the headline numbers on the table, the next step is to see how this performance lines up with the key narratives around HeartFlow's growth potential, risk profile, and path toward better margins. See what the community is saying about HeartFlow NasdaqGS:HTFL Revenue & Expenses Breakdown as at Mar 2026 Advertisement39.9% revenue growth meets persistent US$116.8 million loss  Over the trailing twelve months, HeartFlow generated US$176.0 million in revenue and reported a net loss of US$116.8 million, with basic EPS at a loss of US$3.17 as of Q4 2025 alongside 39.9% year over year revenue growth and forecasts calling for about 19.2% annual revenue growth ahead. Analysts' bullish narrative leans heavily on that 39.9% revenue growth and the expected ~19.2% annual growth, yet the data shows the business is still loss making over the last twelve months, so investors are weighing growth against the US$116.8 million loss and tracking whether the gap between the two meaningfully narrows.\n     Revenue on a trailing basis moved from US$125.8 million in Q4 2024 to US$176.0 million in Q4 2025, while net loss over the latest twelve months sits at US$116.8 million, which keeps profitability as a central watchpoint even as the top line expands. Consensus expectations for continued revenue expansion support the bullish angle on scale benefits, yet the absence of positive EPS in any of the reported quarters shows that the path from revenue growth to earnings is still unproven in the reported numbers.    Bulls pointing to strong top line traction versus ongoing losses may want to see how that debate is laid out in more detail in the 🐂 HeartFlow Bull Case Quarterly losses narrow but remain significant  In FY 2025, quarterly net losses ranged from US$9.2 million to US$50.9 million, with Q4 2025 at a loss of US$24.4 million on US$49.1 million of revenue and a basic EPS loss of US$0.29, compared with Q3 2025 which showed a larger loss of US$50.9 million on slightly lower revenue of US$46.3 million and an EPS loss of US$1.04. Bears focus on the fact that the company is unprofitable over the trailing twelve months and is not forecast to reach profitability within three years, and the quarterly pattern of losses between US$9.2 million and US$50.9 million in FY 2025 gives that cautious view support because, even in higher revenue quarters like Q4, the business still reports a loss and there is no quarter in the data with positive net income.\n     Critics highlight that trailing twelve month net loss of US$116.8 million alongside forecasts for continued losses, which lines up with the bearish concern that scaling revenue alone has not yet translated into sustained profit improvement in the reported figures. What stands out for cautious investors is that EPS remains negative both on a quarterly basis, from a loss of US$5.25 per share in Q1 2025 through a loss of US$0.29 in Q4, and on a trailing basis at a loss of US$3.17, so the bear case that profitability is still some way off is fully consistent with the current numbers.    For readers weighing these continued losses against the growth story, it can help to see how skeptics frame the risks in the 🐻 HeartFlow Bear Case Rich 12.5x P/S and a volatile share price  HeartFlow trades at a P/S of 12.5x compared with peers at 1.8x and the US Healthcare Services industry at 2.1x, while the share price of US$25.89 has been volatile in the past three months and analysts as a group see scope for upside with a consensus target of US$37.67. Consensus narrative notes that the combination of strong trailing revenue growth at 39.9% and analysts' target of US$37.67, which is higher than the current US$25.89 share price, is being balanced against a valuation multiple that is several times peer and industry P/S levels, so investors who accept the consensus view are implicitly comfortable paying a higher multiple today in return for the revenue growth profile and the possibility that losses narrow over time.\n     Supporters point to the higher expected revenue growth rate of around 19.2% annually compared with the broader US market forecast and argue that this growth justifies the 12.5x P/S gap versus peers at 1.8x and the industry at 2.1x. Others focus more on the risk that, with ongoing losses over the last twelve months and no profitability expected within three years, any disappointment in revenue growth or margin trends could matter more because the starting valuation multiple is already elevated relative to the sector.    Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for HeartFlow on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. The mix of growth hopes and clear risks in this story will not feel the same to every investor, so it is worth checking the numbers yourself and deciding how comfortable you are with the trade off between revenue momentum and ongoing losses. To frame that view with both sides of the argument in mind, take a moment to review the 3 key rewards and 2 important warning signs See What Else Is Out There HeartFlow combines strong revenue growth with a trailing twelve month net loss of US$116.8 million and a rich 12.5x P/S multiple against lower valued peers. If you want ideas with more modest valuations and a clearer focus on financial strength, check out the 72 resilient stocks with low risk scores while the numbers are fresh in your mind.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if HeartFlow might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}